Recognition of Non-Operating Income and Expenses
Oncolys BioPharma Inc. (the filing company)
Non-operating income: ¥8 million in interest received, ¥3 million in foreign exchange gains from the revaluation of foreign-currency-denominated assets, and other items. Non-operating expenses: ¥12 million in interest paid, ¥4 million in amortization of restricted stock compensation, and other items.
Non-operating income of ¥12 million and non-operating expenses of ¥19 million (cumulative nine-month period of the fiscal year ending December 2026). From 1 July 2026 to 30 September 2026, non-operating income was ¥5 million and non-operating expenses were ¥19 million. All amounts were recorded as non-operating income and expenses.
Cumulative nine-month period of the fiscal year ending December 2026 (1 January 2026–30 September 2026). Also, the third quarter from 1 July 2026 to 30 September 2026.
As stated in the "Summary of Financial Results for the Third Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Non-consolidated)" published on 6 November 2026.
| Item | Details |
|---|---|
| Event name | Recognition of Non-Operating Income and Expenses |
| Date of occurrence | 1 January 2026–30 September 2026 (recognition period; no single occurrence date stated) |
| Subject Entity | Oncolys BioPharma Inc. (the filing company) |
| Cause | Non-operating income: ¥8 million in interest received, ¥3 million in foreign exchange gains from the revaluation of foreign-currency-denominated assets, and other items. Non-operating expenses: ¥12 million in interest paid, ¥4 million in amortization of restricted stock compensation, and other items. |
| Amount of Impact on Business Performance | Non-operating income of ¥12 million and non-operating expenses of ¥19 million (cumulative nine-month period of the fiscal year ending December 2026). From 1 July 2026 to 30 September 2026, non-operating income was ¥5 million and non-operating expenses were ¥19 million. All amounts were recorded as non-operating income and expenses. |
| Accounting period in which recognized | Cumulative nine-month period of the fiscal year ending December 2026 (1 January 2026–30 September 2026). Also, the third quarter from 1 July 2026 to 30 September 2026. |
| Impact on Earnings Forecast | As stated in the "Summary of Financial Results for the Third Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Non-consolidated)" published on 6 November 2026. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Non-operating income consisted mainly of ¥8 million in interest received and ¥3 million in foreign exchange gains from the revaluation of foreign-currency-denominated assets. Non-operating expenses consisted mainly of ¥12 million in interest paid and ¥4 million in amortization of restricted stock compensation.